Somatostatin

1. Overview

Somatostatin is a peptide hormone that functions as a universal inhibitor of endocrine and exocrine secretions. It plays a key role in regulating the secretion of other hormones such as growth hormone (GH), insulin, glucagon, gastrin, and many others. It acts through both endocrine and paracrine mechanisms and is produced in multiple tissues throughout the body. Somatostatin exists in two biologically active forms and has both central and peripheral regulatory roles in metabolism, digestion, and growth.

2. Location

Somatostatin is produced in several anatomical sites:

• Hypothalamus: Secreted by neuroendocrine neurons in the periventricular nucleus to inhibit growth hormone release from the anterior pituitary.

• Pancreas: Produced by delta (δ) cells of the islets of Langerhans to modulate insulin and glucagon secretion.

• Gastrointestinal tract: Found in D cells throughout the stomach, duodenum, and small intestine where it regulates digestion and nutrient absorption.

• Central nervous system: Also synthesized in various brain regions where it functions as a neurotransmitter or neuromodulator.

3. Structure

Somatostatin exists in two major isoforms:

• Somatostatin-14: A 14–amino acid peptide that is widely distributed in the CNS and peripheral tissues.

• Somatostatin-28: A 28–amino acid peptide with a longer half-life and more prominent action in the gastrointestinal tract.

Both forms are derived from the same precursor protein called preprosomatostatin. Somatostatin acts through five different G protein–coupled receptors (SSTR1 to SSTR5), which are variably expressed in different tissues.

4. Function

Somatostatin acts as a general inhibitory hormone with multiple systemic effects:

• Inhibits growth hormone (GH) secretion from the anterior pituitary.

• Suppresses thyroid-stimulating hormone (TSH) release from the anterior pituitary.

• Inhibits pancreatic secretions of insulin and glucagon.

• Reduces gastrointestinal hormone release including gastrin, cholecystokinin, secretin, and vasoactive intestinal peptide (VIP).

• Decreases gastric acid secretion, motility, and nutrient absorption.

• Inhibits bile and pancreatic enzyme secretion in the digestive system.

5. Physiological role(s)

Somatostatin plays diverse regulatory roles in the endocrine, digestive, and nervous systems:

• Endocrine regulation: Balances the secretion of several key metabolic hormones to prevent overproduction.

• Digestive control: Slows gastric emptying, reduces intestinal blood flow, and inhibits the release of digestive enzymes and hormones.

• Neurotransmission: Acts in the CNS to regulate neural activity, pain perception, and possibly sleep and cognition.

• Paracrine signaling: Locally inhibits adjacent cell hormone secretion in the pancreas and gut mucosa.

6. Clinical Significance

Dysfunction in somatostatin secretion or action can lead to or be associated with several conditions:

• Somatostatinoma:

  • Rare neuroendocrine tumors (usually in the pancreas or duodenum) that secrete excessive somatostatin.

  • Symptoms include diabetes mellitus, gallstones, steatorrhea, and hypochlorhydria due to widespread inhibition of pancreatic and GI secretions.

• Diabetes and hypoglycemia:

  • Because somatostatin inhibits both insulin and glucagon, abnormalities in its levels can disrupt glucose homeostasis.

• Acromegaly and pituitary disorders:

  • Somatostatin analogs like octreotide and lanreotide are used to treat growth hormone–secreting pituitary tumors (acromegaly).

• Gastrointestinal disorders:

  • Somatostatin analogs are used to treat conditions like VIPoma, carcinoid syndrome, severe diarrhea, and bleeding from esophageal varices.

• Neuroendocrine tumors:

  • Many NETs express somatostatin receptors and can be imaged using somatostatin receptor scintigraphy (OctreoScan) or treated with peptide receptor radionuclide therapy (PRRT).